Vicarious Surgical to Report Third Quarter 2025 Financial Results on November 12, 2025 Share WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. ("Vicarious Surgical†or the "Company†) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will now report financial results for the third quarter ended September 30, 2025 after the market closes on Wednesday, November 12, 2025. Company management will host a corres ...

UFP Technologies (NasdaqCM:UFPT) Q3 2025 Earnings Call November 04, 2025 08:30 AM ET Speaker2Good day and welcome to the UFP Technologies third quarter 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask a question. To ask a question, you may press star then one on a touchstone phone. To withdraw a question, plea ...

This stock has averaged annual gains of nearly 24% over the past decade -- and its future is bright, too.I'm invested in several healthcare stocks, and the one that I'm most excited about is Intuitive Surgical (ISRG -3.19%). The stock is down 15.5% year to date as I write this, making it more attractively priced than it was last year.It's a major specialist in robotic surgery equipment, boasting more than 16 million procedures performed on its equipment and more than 9,900 machines installed in hospitals ar ...

Core Insights - Intuitive has announced new software capabilities for the da Vinci 5 system aimed at enhancing surgical efficiency and patient outcomes through real-time insights [1][12] Group 1: New Features - The da Vinci 5 system boasts over 10,000 times the computing power of its predecessor, da Vinci Xi, allowing for continuous optimization and performance enhancements through software updates [2] - Key new features include Force Gauge, In-Console Video Replay, and Network CCM, all designed to improve surgical precision and efficiency [4][10] Group 2: Force Gauge - The Force Gauge provides a real-time visual indicator of the force applied to tissue during surgery, measuring within a range of 0–6.5 Newtons, which helps surgeons apply less force and reduce tissue trauma [5][7] - Dr. Andrea Pakula from Adventist Health noted that the Force Feedback technology has led to consistently lower force application during procedures, supporting safer surgical practices [6][7] Group 3: In-Console Video Replay - In-Console Video Replay allows surgeons to review key moments of the procedure without leaving the console, enhancing situational awareness and decision-making [8][9] - This feature captures the entire procedure locally, facilitating collaborative reviews and improving overall procedural safety [9] Group 4: Network CCM - Network CCM enables remote software updates for the da Vinci 5 system, reducing administrative burdens for hospital teams and ensuring timely access to new features [10] - The new software capabilities have received 510(k) clearance from the U.S. FDA, reflecting ongoing innovation and customer feedback integration [12]

Group 1: Northstar Clean Technologies - Northstar Clean Technologies has successfully produced high-quality solid asphalt pellets from end-of-life tear-off shingles at its Calgary facility, marking a significant milestone in its recycling operations [1] - This achievement builds on the company's previous success in producing liquid asphalt from manufacturing waste shingles, contributing to waste diversion from landfills and creating new market opportunities [2] Group 2: Memorial Care - Memorial Care has introduced the Intuitive Da Vinci 5 surgical system across its hospitals, becoming one of the first health systems in Southern California to adopt this advanced robotic technology [2] - The Da Vinci 5 system enhances surgeons' precision, control, and real-time digital integration, reinforcing Memorial Care's commitment to innovation and improved patient outcomes [2] Group 3: Eco-wave Power Global - Eco-wave Power Global has launched the first US onshore wave energy project at the Port of Los Angeles, marking a historic milestone for renewable energy in the country [3] - The demonstration site utilizes floaters to harness wave motion for electricity, laying the groundwork for future commercial-scale deployment and positioning the company as a leader in the US wave energy sector [3] Group 4: XDI Aerospace - XDI Aerospace has completed initial flight operations for its Sparrow and Kestrel subscale aircraft, marking key progress toward its full-scale Trifan 600 demonstrator [3] - Successful tests validated aerodynamic performance and stability, reducing development risk and keeping the program on track for future milestones [4]

Surgical Procedure Evolution - Open surgery involved large incisions and longer recovery times [2][3][8] - Laparoscopic surgery uses smaller incisions, CO2 inflation, and 2D screen projection [9][10] - Robotic surgery enhances instrument movement precision within the abdomen [16] Technological Advancements in Robotics - Robotic technology originated from military research (DARPA) in the 1980s [23] - The Da Vinci 5 robot (DV5), launched in August 2024, is the most precise robot [22] - Robotic consoles have evolved significantly from the first prototype in 1996 to the latest versions [17][18][23] Surgical Techniques and Training - Traditional surgical training in the 19th century involved large incisions and auditorium settings [7][8] - Laparoscopic surgery skills can be correlated with video game proficiency due to 2D image translation [12][13] - Robotic surgery allows surgeons to control four instruments simultaneously using hand clutches [19] Operating Room Dynamics - Laparoscopic surgery typically requires a surgeon, surgical tech, and potentially up to four people [13][14] - Robotic surgery can reduce the number of bedside personnel needed [20] - Modern operating rooms (ORs) are equipped with screens on every wall and robotic systems [21][22]

Company Overview - SS Innovations International, Inc. is a developer of innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [3] - The company is headquartered in India and plans to expand its global presence with user-friendly and cost-effective surgical robotic solutions [3] Recent Developments - The first robotic cardiac surgery in the Americas was successfully performed using the SSi Mantra 3 surgical robotic system on June 8, 2025, by Dr. Juan Zuniga in Guayaquil, Ecuador [1] - The procedure involved a robotic Atrial Septal Defect closure, which repairs a hole between the upper two chambers of the heart [1] Technology Features - The SSi Mantra surgical robotic system is a modular, multi-arm system featuring advanced technology such as 3 to 5 robotic arms, a 3D 4K monitor, and a touch panel for patient information [4] - It utilizes over 40 different types of robotic endo-surgical instruments to support various specialties, including cardiac surgery [4] - The system has been clinically validated in India for over 100 different types of surgical procedures [4] Surgical Experience - Dr. Zuniga reported that the SSi Mantra system was easy to handle, resulting in effective outcomes and faster recovery for patients due to its minimally invasive nature [2] - The precision of the robotic system enhances the surgeon's confidence in performing sutures and tissue manipulation [2] Hospital Adoption - Interhospital in Guayaquil is the first hospital in South America to install the SSi Mantra system and has utilized it for various complex surgical procedures since its installation [2]

Summary of Procept BioRobotics (PRCT) FY Conference Call - June 04, 2025 Company Overview - Procept BioRobotics is a surgical robotic company aiming to become a global leader in urology [3][4] - The company focuses on treating Benign Prostatic Hyperplasia (BPH), a condition affecting a significant portion of the male population [5] Industry Insights - BPH affects one in two men aged 50-60, with 40 million men in the U.S. suffering from this condition [5] - There is a large unmet clinical need, with only 12 million of the 40 million men under medical management [6] - The majority of men avoid surgical options due to side effects associated with current treatments [6][7] Product and Technology - Aquablation therapy is designed to address the unmet clinical need for BPH treatment, effective for all prostate sizes and shapes [6][9] - The technology utilizes an automated water jet, avoiding unnecessary damage to surrounding tissue [9] - Clinical studies show that aquablation has superior safety outcomes compared to traditional resective procedures like TURP [11][12] Market Access and Reimbursement - Full Medicare coverage is available for aquablation, with 95% of eligible patients having access to the treatment [15] - The facility payment for aquablation is just over $9,200, with expectations for reimbursement to align with other resective procedures [36][37] Financial Performance - The company reported a revenue of $69.2 million for the first quarter, a 55% year-over-year growth [22] - The installed base in the U.S. reached 547 systems, with significant international revenue growth, particularly in the U.K. and Japan [23][24] - Revenue guidance for 2025 is set at $323 million, with an expected growth rate of 63% to 64.5% [24] Future Opportunities - Procept is exploring the use of aquablation for prostate cancer treatment, addressing a significant unmet clinical need [16][18] - There are over 3 million men in the U.S. with prostate cancer, with 300,000 new cases annually [16] - The company is conducting clinical studies to demonstrate the safety and efficacy of aquablation in prostate cancer patients [19][22] Challenges and Execution - The company is focused on surgeon retention and increasing procedure volumes, with over 30,000 cases performed in the U.S. last year [32][33] - The transition from Category III to Category I reimbursement codes is a key milestone, expected to simplify pre-authorization processes [36][39] Conclusion - Procept BioRobotics is positioned to capitalize on the growing demand for effective BPH and prostate cancer treatments through innovative technology and strong clinical data [44]

Core Insights - SS Innovations International, Inc. reported record quarterly revenue of $5.1 million for Q1 2025, a 40.8% increase from $3.6 million in Q1 2024, driven by higher sales of the SSi Mantra 3 surgical robotic system [4][6] - The company plans to submit a De Novo application to the FDA for the SSi Mantra 3 by the end of July 2025, aiming for approval in the U.S. and European markets [4][6] Financial Performance - Revenue increased by 40.8% to $5.1 million from $3.6 million in Q1 2024 [6] - Gross margin improved by 121 basis points to 21.23% from 20.02% in Q1 2024 [6] - Gross profit rose by 49.3% to $1.1 million from $0.7 million in Q1 2024 [6] - Net loss decreased to $5.7 million, or $(0.03) per diluted share, compared to a net loss of $9.8 million, or $(0.06) per diluted share, in Q1 2024 [6] Business Highlights - SSi Mantra installations totaled 15, a 66.7% increase from 9 installations in Q1 2024 [6] - Cumulative installed base of SSi Mantra reached 78, with cumulative surgeries totaling 3,568 [6][8] - Significant growth in instrument sales (302.7%) and warranty sales (1,202.3%) compared to Q1 2024 [8] Strategic Developments - The company uplisted to The Nasdaq Capital Market on April 25, 2025, marking a milestone for global expansion [3][4] - Plans to expand market presence beyond the seven countries where the SSi Mantra has been cleared, focusing on the EU and U.S. [4] Product Innovations - The SSi Mantra 3 surgical robotic system enabled the world's first robotic cardiac telesurgery [7] - The system received regulatory approvals in the Philippines and Ukraine, enhancing its market potential [7]

Financial Data and Key Metrics Changes - Total operating expenses for full year 2024 were $66.6 million, down 17% year-over-year [24] - R&D expenses for the full year 2024 were $40.2 million, down from $47.6 million in 2023 [24] - GAAP net loss for full year was $63.2 million, equating to a net loss of $10.74 per share, compared to a GAAP net loss of $71.1 million or $14.60 per share for the full year 2023 [25] Business Line Data and Key Metrics Changes - General and administrative expenses totaled $21.9 million in the full year 2024, down from $26.9 million in 2023 [24] - Sales and marketing expenses were $4.5 million compared to $6.2 million in the prior year [24] Market Data and Key Metrics Changes - The company has expanded its partnerships with leading U.S. hospital systems, including LSU Health New Orleans, Temple Health, and University of Illinois Health [13][15] - The company is preparing for its first clinical use of the Version 1.0% system, which is expected to treat patients later in the year [21] Company Strategy and Development Direction - The company aims to transition into a clinical stage company in 2025, with a focus on robotic surgery innovations [8] - The Version 1.0% system is designed to deliver differentiated value to patients, surgeons, and hospitals, with a focus on minimally invasive outcomes [10][12] - The company is building a robust supply chain and manufacturing foundation to support its clinical trials and future growth [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the successful completion of the Version 1.0% system integration and the potential impact on surgical procedures [9][28] - The company anticipates treating its first clinical patients by year-end 2025, with a de novo submission expected to be late in 2026 [21][26] Other Important Information - The company has faced some procurement challenges with key suppliers, but has managed to mitigate the impact on its timelines [20][36] - A new CFO, Sarah Romano, will join the company on April 1, bringing extensive financial leadership experience [22][23] Q&A Session Summary Question: Can you provide details on the supplier dynamic and its impact on clinical trial manufacturing? - Management acknowledged material procurement challenges with key suppliers that led to delays in component deliverables, but noted that they have resumed production [35][37] Question: When do you anticipate the clinical trial beginning? - Management indicated that the first patients will be treated later in the year, with plans to kick off pivotal trials shortly after [41][42] Question: Can you provide timing around the dossier submission? - The dossier submission is expected around the middle of the year, with the first patient timing dependent on approval [51] Question: What were the results of the cadaver lab tests? - The cadaver labs successfully performed ventral hernia repairs, and management expressed confidence in the system's performance [61] Question: Any updates on clinical trial design and patient expectations? - Management confirmed that trial design will be finalized after the first patients, allowing for flexibility in protocol adjustments [64]